Hemogenyx Pharmaceuticals Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Vladislav Sandler
Chief Executive Officer (CEO)
UK£282.0k
Compensación total
| Porcentaje del salario del CEO | 97.9% |
| Permanencia del CEO | 10.4yrs |
| Participación del CEO | 3.1% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 6.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -UK£7m |
| Sep 30 2023 | n/a | n/a | -UK£7m |
| Jun 30 2023 | n/a | n/a | -UK£7m |
| Mar 31 2023 | n/a | n/a | -UK£6m |
| Dec 31 2022 | UK£282k | UK£276k | -UK£4m |
| Sep 30 2022 | n/a | n/a | -UK£3m |
| Jun 30 2022 | n/a | n/a | -UK£3m |
| Mar 31 2022 | n/a | n/a | -UK£4m |
| Dec 31 2021 | UK£213k | UK£206k | -UK£5m |
| Sep 30 2021 | n/a | n/a | -UK£5m |
| Jun 30 2021 | n/a | n/a | -UK£5m |
| Mar 31 2021 | n/a | n/a | -UK£3m |
| Dec 31 2020 | UK£205k | UK£200k | -UK£2m |
| Sep 30 2020 | n/a | n/a | -UK£2m |
| Jun 30 2020 | n/a | n/a | -UK£2m |
| Mar 31 2020 | n/a | n/a | -UK£2m |
| Dec 31 2019 | UK£149k | UK£145k | -UK£1m |
| Sep 30 2019 | n/a | n/a | -UK£2m |
| Jun 30 2019 | n/a | n/a | -UK£2m |
| Mar 31 2019 | n/a | n/a | -UK£2m |
| Dec 31 2018 | UK£98k | UK£94k | -UK£2m |
| Sep 30 2018 | n/a | n/a | -UK£2m |
| Jun 30 2018 | n/a | n/a | -UK£3m |
| Mar 31 2018 | n/a | n/a | -UK£3m |
| Dec 31 2017 | UK£79k | UK£79k | -UK£2m |
Compensación vs. Mercado: La compensación total ($USD352.88K) de Vladislav está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD345.26K).
Compensación vs. Ingresos: La compensación de Vladislav ha aumentado mientras la empresa no es rentable.
CEO
Vladislav Sandler (58 yo)
10.4yrs
Permanencia
UK£282,000
Compensación
Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 6.6yrs | UK£282.00k | 3.1% £ 650.2k | |
| Independent Co-Founder & Non-Executive Director | 6.6yrs | UK£57.00k | 5.6% £ 1.2m | |
| Clinical Advisor & Medical Director | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.2yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 8.8yrs | UK£50.00k | 0.42% £ 87.6k | |
| Board Observer & Business Advisor | 2.8yrs | sin datos | sin datos | |
| Independent Chairman & Chairman of Advisory Board | 6.7yrs | UK£15.00k | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos |
6.6yrs
Permanencia media
67.5yo
Promedio de edad
Junta con experiencia: La junta directiva de HEMO se considera experimentada (6.5 años de antigüedad promedio).